NeuroOne Medical Technologies (NASDAQ:NMTC) Director Sells $31,800.00 in Stock

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Director Mark Christianson sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the transaction, the director directly owned 20,692 shares of the company’s stock, valued at $65,800.56. The trade was a 32.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NeuroOne Medical Technologies Price Performance

NASDAQ NMTC opened at $3.00 on Friday. The stock’s 50 day simple moving average is $3.80 and its 200-day simple moving average is $4.38. The company has a market cap of $26.10 million, a PE ratio of -3.53 and a beta of 0.54. NeuroOne Medical Technologies Corporation has a 1-year low of $2.89 and a 1-year high of $6.96.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $2.58 million. On average, equities research analysts anticipate that NeuroOne Medical Technologies Corporation will post -0.36 EPS for the current fiscal year.

Institutional Trading of NeuroOne Medical Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the company. XTX Topco Ltd lifted its holdings in NeuroOne Medical Technologies by 321.1% in the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after acquiring an additional 65,163 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in NeuroOne Medical Technologies during the fourth quarter worth $36,000. Essex Investment Management Co. LLC purchased a new stake in NeuroOne Medical Technologies in the fourth quarter valued at $143,000. Renaissance Technologies LLC raised its position in NeuroOne Medical Technologies by 10.2% in the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after purchasing an additional 70,428 shares during the period. Finally, Legato Capital Management LLC acquired a new position in shares of NeuroOne Medical Technologies in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 16.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NMTC shares. Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. Weiss Ratings lowered shares of NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Finally, LADENBURG THALM/SH SH upped their price objective on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, NeuroOne Medical Technologies has a consensus rating of “Hold” and an average target price of $11.67.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.